An FDA complete response letter for idebenone in LHON indicates unresolved NDA deficiencies and necessitates additional data before approval can be reconsidered. Priority review status and a February ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A long-term phase 4 trial investigating Raxone for the ...

A Prescription Drug User Fee Act target date of February 28, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic neuropathy (LHON). The study was conducted in collaboration with the Seoul National ...

Leber hereditary optic neuropathy, also known as LHON or Leber optic neuropathy, is an inherited genetic condition. It often causes loss of central vision, starting in one eye and eventually affecting ...

Please provide your email address to receive an email when new articles are posted on . A significant improvement of visual acuity was reported in eyes treated with a unilateral intravitreal injection ...

A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic neuropathy (LHON). The study was conducted in collaboration with the Seoul National ...

A research team led by Professor Hyunji Lee of the Department of Convergence Medicine at Korea University College of Medicine (co-first authors: PhD candidates Sanghun Kim, Ji Eun Kim, and Sungjin Ju; ...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene ...

Considering taking supplements to treat Leber hereditary optic neuropathy? Below is a list of common natural remedies used to treat or reduce the symptoms of Leber hereditary optic neuropathy. Follow ...